Yoshiaki Fujimori - Boston Scientific Independent Director
| BSX Stock | USD 100.69 0.82 0.81% |
Director
Mr. Yoshiaki Fujimori is Independent Director of the Company. Mr. Fujimori is currently an adviser to the LIXIL Group Corporationrationration, a position he has held since June 2016, and was the President and Chief Executive Officer of the LIXIL Group Corporation from August 2011 to June 2016. Prior to joining LIXIL, he was Chairman, President and Chief Executive Officer of GE Japan from January 2008 to June 2011. In his 25 years at GE, beginning in October 1986, he held a variety of positions including Senior Vice President and Chief Executive Officer of a number of Asian and global business divisions, including Medical Systems, Plastics, and Capital. Mr. Fujimori also served as a member of the GE Corporationrationrate Executive Council from 2001 to 2010. He formerly served as a Director of the Japan Construction Material Housing Equipment Industries Federation and Tokyo Electric Power Company Holdings. since 2016.
| Age | 69 |
| Tenure | 9 years |
| Address | 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234 |
| Phone | 508 683 4000 |
| Web | https://www.bostonscientific.com |
Boston Scientific Management Efficiency
The company has Return on Asset of 0.0504 % which means that on every $100 spent on assets, it made $0.0504 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0889 %, implying that it generated $0.0889 on every 100 dollars invested. Boston Scientific's management efficiency ratios could be used to measure how well Boston Scientific manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Boston Scientific's Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.13 in 2025, whereas Return On Equity is likely to drop 0.07 in 2025. At this time, Boston Scientific's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 34.1 B in 2025, whereas Intangible Assets are likely to drop slightly above 5 B in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Nirav Shah | STERIS plc | 47 | |
| Edward Liddy | Abbott Laboratories | 74 | |
| Srikant Datar | Stryker | 68 | |
| Katarzyna MazurHofsaess | Smith Nephew SNATS | 57 | |
| Michael Wood | STERIS plc | 74 | |
| Syed Jafry | Zimmer Biomet Holdings | 57 | |
| Mary Brainerd | Stryker | 67 | |
| Richard Breeden | STERIS plc | 70 | |
| Darren McDew | Abbott Laboratories | 60 | |
| Sherilyn McCoy | Stryker | 62 | |
| David Lewis | STERIS plc | 75 | |
| Kieran Gallahue | Edwards Lifesciences Corp | 57 | |
| Loyal Wilson | STERIS plc | 70 | |
| Michael Michelson | Zimmer Biomet Holdings | 69 | |
| Rajeev Suri | Stryker | 53 | |
| Ronda Stryker | Stryker | 66 | |
| John Rogers | Smith Nephew SNATS | 56 | |
| Angela Fuente | Edwards Lifesciences Corp | N/A | |
| Jacqueline Kosecoff | STERIS plc | 71 | |
| James Lenehan | Medtronic PLC | 71 | |
| Paul LaViolette | Edwards Lifesciences Corp | 63 | |
Management Performance
| Return On Equity | 0.0889 | ||||
| Return On Asset | 0.0504 |
Boston Scientific Corp Leadership Team
Elected by the shareholders, the Boston Scientific's board of directors comprises two types of representatives: Boston Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boston. The board's role is to monitor Boston Scientific's management team and ensure that shareholders' interests are well served. Boston Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boston Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Ludwig, Lead Independent Director | ||
| Donna James, Independent Director | ||
| Stephen MacMillan, Independent Director | ||
| Michael Mahoney, Chairman of the Board, President, Chief Executive Officer | ||
| Emily Woodworth, Global VP | ||
| Kevin Ballinger, Executive Vice President and Global President - Interventional Cardiology | ||
| Desiree RallsMorrison, Senior Vice President General Counsel, Corporate Secretary | ||
| Maulik Nanavaty, Senior Vice President and President - Neuromodulation | ||
| Ian Meredith, Executive Vice President Global Chief Medical Officer | ||
| David Pierce, Executive Vice President and President, MedSurg and President - Endoscopy | ||
| Ellen Zane, Independent Director | ||
| Joseph Fitzgerald, Executive Vice President, President, Interventional Cardiology | ||
| Eric Thepaut, Executive Vice President and President - Europe, Middle East and Africa | ||
| Daniel Brennan, CFO, Principal Accounting Officer and Executive VP | ||
| Nelda Connors, Independent Director | ||
| Brenda Becker, Senior Affairs | ||
| Wendy Carruthers, Executive Vice President - Human Resources | ||
| Jodi Eddy, Senior Vice President and Chief Information and Digital Officer | ||
| Miriam Osullivan, Senior Officer | ||
| Catherine Jennings, VP Interventions | ||
| John Sorenson, Senior Vice President - Manufacturing and Supply Chain | ||
| Arthur Butcher, Executive Vice President and President, Asia Pacific | ||
| Daniel CPA, Executive CFO | ||
| MD FACC, Senior Officer | ||
| Edward Mackey, Executive Vice President - Global Operations | ||
| Vance JD, General VP | ||
| Scott Olson, Senior Vice President, President - Cardiac Rhythm Management and Diagnostics | ||
| Vance Brown, Senior Vice President General Counsel, Corporate Secretary | ||
| Charles Dockendorff, Independent Director | ||
| Mary Moynihan, Senior Officer | ||
| John Sununu, Independent Director | ||
| Jeffrey Mirviss, Executive Vice President and President - Peripheral Interventions | ||
| Yoshiaki Fujimori, Independent Director | ||
| David Wichmann, Independent Director | ||
| David Roux, Independent Director | ||
| Susan Lisa, VP, Investor Relations | ||
| Jonathan Monson, Chief Accounting Officer, Vice President Global Controller | ||
| Jeffrey MBA, Executive Interventions | ||
| Meghan Scanlon, Senior Vice President and President - Urology and Pelvic Health |
Boston Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boston Scientific a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0889 | ||||
| Return On Asset | 0.0504 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 159.66 B | ||||
| Shares Outstanding | 1.48 B | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 93.15 % | ||||
| Number Of Shares Shorted | 12.87 M | ||||
| Price To Earning | 107.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Boston Stock Analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.